PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 1, 2025Neuro-Oncology0 citationsOpen Access

Combination PARP Inhibitor and Temozolomide Therapy in Recurrent Glioma Outcomes

NCOG-32. Clinical outcomes of combination PARP inhibitor and temozolomide therapy in recurrent glioma: Insights from a single institution experience

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNishika KarbhariJCJian CampianJSJann Sarkaria

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows PARP inhibitor treatment in glioblastoma patients suggesting potential for improved outcomes.

Key Points

  • To evaluate clinical outcomes of combining PARP inhibitors with temozolomide in recurrent glioma.
  • Retrospective analysis of neuro-oncology patients treated with PARP inhibitors and temozolomide.
  • Inclusion criteria: treatment duration > 1 month, off-label use from 2010 to 2025.
  • Patients reviewed for tumor types, treatment history, and progression outcomes.
  • Nineteen patients treated; median age was 45, predominantly female (47%).
  • Tumor types included glioblastoma, various graded astrocytomas and oligodendrogliomas.
  • Median overall survival varied by tumor type, with GBM showing 34.9 months on average.

Cite This Study

Karbhari et al. (2025) studied this question.

synapsesocial.com/papers/6925435ec0ce034ddc358116https://doi.org/10.1093/neuonc/noaf201.1299
View Full Paper
Ask AI
Bookmark
Share